Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant Trop2 (Sacituzumab Biosimilar) antibody

This Humanized Monoclonal antibody specifically detects Trop2 (Sacituzumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.
Catalog No. ABIN7795133

Quick Overview for Recombinant Trop2 (Sacituzumab Biosimilar) antibody (ABIN7795133)

Target

Trop2 (Sacituzumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 4
  • 1
Humanized

Clonality

  • 4
  • 1
Monoclonal

Conjugate

  • 4
  • 1
This Trop2 (Sacituzumab Biosimilar) antibody is un-conjugated

Application

  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade

Research Grade
  • Expression System

    Mammalian cells

    Purpose

    Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg

    Characteristics

    What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

    Purification

    Protein A or G affinity column

    Purity

    >95 % by reducing SDS-PAGE

    Endotoxin Level

    Less than 0.5 EU/mg of protein as determined by LAL method

    Immunogen

    Human Trop-2
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    > 3 mg/mL

    Storage

    4 °C,-20 °C

    Storage Comment

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Target

    Trop2 (Sacituzumab Biosimilar)

    Alternative Name

    Sacituzumab Biosimilar

    Target Type

    Biosimilar
You are here:
Chat with us!